L8 HAS NO ANSWERS
L8 STR



VAR G1=10/11/15
VAR G2=ME/ET/N-PR/I-PR/N-BU/I-BU/T-BU
VAR G3=2/1/6/5
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 11 9
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

=> s l8 ful
FULL SEARCH INITIATED 09:59:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 856768 TO ITERATE

100.0% PROCESSED 856768 ITERATIONS 37 ANSWERS
SEARCH TIME: 00.00.08

L10 37 SEA SSS FUL L8

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 186.84 374.86

FILE 'CAPLUS' ENTERED AT 09:59:24 ON 20 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Oct 2009 VOL 151 ISS 17
FILE LAST UPDATED: 19 Oct 2009 (20091019/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l10
L11   12 L10

=> d bib hitstr 1-12

L11 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN   2007:963884 CAPLUS
DN   147:322994
TI   Preparation of heterocyclic compounds having 5-HT6 receptor affinity for
     treating CNS, gastrointestinal, and polyglutamine-repeat disorders
IN   Dunn, Robert; Nguyen, Truc Minh; Xie, Wenge; Tehim, Ashok
PA   Memory Pharmaceuticals Corporation, USA
SO   PCT Int. Appl., 179pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007098418	A1	20070830	WO 2007-US62340	20070216
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2007217040	A1	20070830	AU 2007-217040	20070216
	CA 2637531	A1	20070830	CA 2007-2637531	20070216
	US 20080039462	A1	20080214	US 2007-676203	20070216
	EP 1984351	A1	20081029	EP 2007-757140	20070216
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	MX 2008010481	A	20081219	MX 2008-10481	20080814
PRAI	US 2006-774399P	P	20060217		
	WO 2007-US62340	W	20070216		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:322994
IT 116480-55-8P, 3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-5-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. having 5-HT6 receptor affinity for treating CNS, gastrointestinal, and polyglutamine-repeat disorders)
RN 116480-55-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:673109 CAPLUS
DN 143:172754
TI Preparation of 7-indolecarboxamides as IKK2 kinase inhibitors for the treatment of such as inflammatory and tissue repair disorders
IN Baldwin, Ian Robert; Bamborough, Paul; Christopher, John Andrew; Kerns, Jeffrey K.; Longstaff, Timothy; Miller, David Drysdale
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005067923	A1	20050728	WO 2005-GB85	20050113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005205090	A1	20050728	AU 2005-205090	20050113
CA 2552953	A1	20050728	CA 2005-2552953	20050113
EP 1703905	A1	20060927	EP 2005-701855	20050113
EP 1703905	B1	20081112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1933830	A	20070321	CN 2005-80008362	20050113
BR 2005006802	A	20070529	BR 2005-6802	20050113
JP 2007517848	T	20070705	JP 2006-548393	20050113
AT 413877	T	20081115	AT 2005-701855	20050113

	ES 2317184	T3	20090416	ES 2005-701855	20050113
	ZA 2006004855	A	20071128	ZA 2006-4855	20060613
	IN 2006DN03579	A	20070831	IN 2006-DN3579	20060621
	US 20080269200	A1	20081030	US 2006-597154	20060713
	MX 2006008080	A	20060920	MX 2006-8080	20060714
	NO 2006003676	A	20061013	NO 2006-3676	20060815
	HK 1098047	A1	20090529	HK 2007-102877	20070316
PRAI	GB 2004-895	A	20040115		
	WO 2005-GB85	W	20050113		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:172754; MARPAT 143:172754

IT 860626-09-1P, 3-(1-Ethyl-3-piperidinyl)-5-phenyl-1H-indole-7-carboxamide 860626-21-7P, 3-(1-Ethyl-4-piperidinyl)-5-phenyl-1H-indole-7-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of indolecarboxamides as IKK2 kinase inhibitors)

RN 860626-09-1 CAPLUS

CN 1H-Indole-7-carboxamide, 3-(1-ethyl-3-piperidinyl)-5-phenyl- (CA INDEX NAME)



RN 860626-21-7 CAPLUS

CN 1H-Indole-7-carboxamide, 3-(1-ethyl-4-piperidinyl)-5-phenyl- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1999:795681 CAPLUS

DN 132:35606

TI Preparation of multibinding piperidinylindole derivatives as therapeutic agents that modulate 5-HT receptors

IN Marquess, Daniel; Griffin, John H.; Choi, Seok-Ki

PA Advanced Medicine, Inc., USA

SO PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 31

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9964044	A1	19991216	WO 1999-US12751	19990607
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318894	A1	19991216	CA 1999-2318894	19990604
AU 9945435	A	19991230	AU 1999-45435	19990604
EP 1003540	A1	20000531	EP 1999-928344	19990604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517457	T	20020618	JP 2000-553099	19990604
CA 2318055	A1	19991216	CA 1999-2318055	19990607
CA 2318286	A1	19991216	CA 1999-2318286	19990607
CA 2319068	A1	19991216	CA 1999-2319068	19990607
CA 2319159	A1	19991216	CA 1999-2319159	19990607
CA 2319174	A1	19991216	CA 1999-2319174	19990607
CA 2319175	A1	19991216	CA 1999-2319175	19990607
CA 2319496	A1	19991216	CA 1999-2319496	19990607
CA 2319751	A1	19991216	CA 1999-2319751	19990607
CA 2319756	A1	19991216	CA 1999-2319756	19990607
CA 2321170	A1	19991216	CA 1999-2321170	19990607
CA 2321273	A1	19991216	CA 1999-2321273	19990607
AU 9944234	A	19991230	AU 1999-44234	19990607
AU 9944253	A	19991230	AU 1999-44253	19990607
AU 9944265	A	19991230	AU 1999-44265	19990607
AU 9945491	A	19991230	AU 1999-45491	19990607
AU 9945520	A	19991230	AU 1999-45520	19990607
AU 9946727	A	19991230	AU 1999-46727	19990607
AU 9946751	A	19991230	AU 1999-46751	19990607
AU 9946752	A	19991230	AU 1999-46752	19990607
AU 9946754	A	19991230	AU 1999-46754	19990607
EP 1019360	A1	20000719	EP 1999-930123	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1080080	A1	20010307	EP 1999-930158	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083917	A1	20010321	EP 1999-927291	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083918	A1	20010321	EP 1999-927317	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083893	A1	20010321	EP 1999-927331	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083888	A1	20010321	EP 1999-928425	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085887	A2	20010328	EP 1999-928349	19990607

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085870 A2 20010328 EP 1999-930157 19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1094826 A1 20010502 EP 1999-930156 19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1100519 A1 20010523 EP 1999-930155 19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1107753 A1 20010620 EP 1999-928457 19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2002517420 T 20020618 JP 2000-553004 19990607
JP 2002517459 T 20020618 JP 2000-553102 19990607
JP 2002517463 T 20020618 JP 2000-553110 19990607
CA 2319497 A1 19991216 CA 1999-2319497 19990608
CA 2319643 A1 19991216 CA 1999-2319643 19990608
CA 2319651 A1 19991216 CA 1999-2319651 19990608
CA 2320926 A1 19991216 CA 1999-2320926 19990608
CA 2321120 A1 19991216 CA 1999-2321120 19990608
CA 2321152 A1 19991216 CA 1999-2321152 19990608
CA 2319650 A1 19991229 CA 1999-2319650 19990608
AU 9943368 A 19991230 AU 1999-43368 19990608
AU 9943376 A 19991230 AU 1999-43376 19990608
AU 9946747 A 19991230 AU 1999-46747 19990608
AU 9952039 A 19991230 AU 1999-52039 19990608
AU 9946776 A 20000110 AU 1999-46776 19990608
EP 1082289 A1 20010314 EP 1999-930185 19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083921 A1 20010321 EP 1999-955430 19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085889 A2 20010328 EP 1999-928451 19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085847 A2 20010328 EP 1999-928520 19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085868 A1 20010328 EP 1999-930150 19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085894 A1 20010328 EP 1999-937155 19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1102597 A1 20010530 EP 1999-955431 19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
SG 83723 A1 20011016 SG 1999-2842 19990608
JP 2002517442 T 20020618 JP 2000-553068 19990608
US 6288055 B1 20010911 US 2000-499476 20000207
ZA 2000003475 A 20011011 ZA 2000-3475 20000711
ZA 2000004083 A 20011112 ZA 2000-4083 20000810
ZA 2000004085 A 20011112 ZA 2000-4085 20000810
ZA 2000004087 A 20011113 ZA 2000-4087 20000810
ZA 2000004084 A 20011119 ZA 2000-4084 20000810
ZA 2000004561 A 20011130 ZA 2000-4561 20000831
ZA 2000004565 A 20011130 ZA 2000-4565 20000831
US 20030087306 A1 20030508 US 2001-15534 20011213

PRAI US 1998-88466P P 19980608
US 1998-92938P P 19980715
US 1998-96606P P 19980814
WO 1999-US11786 W 19990604
US 1999-327044 B1 19990607
WO 1999-US11803 W 19990607
WO 1999-US11805 W 19990607
WO 1999-US12669 W 19990607
WO 1999-US12673 W 19990607
WO 1999-US12727 W 19990607
WO 1999-US12728 W 19990607
WO 1999-US12730 W 19990607
WO 1999-US12731 W 19990607
WO 1999-US12751 W 19990607
WO 1999-US12778 W 19990607
WO 1999-US12782 W 19990607
US 1999-327904 B1 19990608
WO 1999-US12626 W 19990608
WO 1999-US12770 W 19990608
WO 1999-US12876 W 19990608
WO 1999-US12907 W 19990608
WO 1999-US12989 W 19990608
WO 1999-US12994 W 19990608
WO 1999-US12995 W 19990608
US 2000-493462 B1 20000128
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 132:35606
IT 252355-48-9P 252355-49-0P 252355-50-3P
252355-51-4P 252355-52-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of multibinding piperidinylindole derivs. as therapeutic agents that modulate 5-HT receptors and are useful for the treatment of migraine)
RN 252355-48-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(1H-indol-3-yl)ethyl]-N-methyl-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 252355-49-0 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(1H-indol-3-yl)ethyl]-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 252355-50-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 252355-51-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(6-methoxy-1H-indol-3-yl)ethyl]-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 252355-52-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(1H-indol-3-yl)-1-methylethyl]-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:197401 CAPLUS
DN 128:257330
OREF 128:50942h,50943a
TI Preparation of piperidinylindoles and related compounds as serotonin 5-HT1F agonists
IN Johnson, Kirk W.; Phebus, Lee A.
PA Eli Lilly and Company, USA; Johnson, Kirk W.; Phebus, Lee A.
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811895	A1	19980326	WO 1997-US14576	19970815
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9740748	A	19980414	AU 1997-40748	19970815
	EP 832650	A2	19980401	EP 1997-307202	19970917
	EP 832650	A3	19980902		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1996-25271P	P	19960918		
	WO 1997-US14576	W	19970815		

OS MARPAT 128:257330
IT 182564-21-2P 182564-22-3P 182564-23-4P
182564-24-5P 182564-25-6P 182564-36-9P
201857-22-9P 201857-23-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidinylindoles and related compds. as serotonin 5-HT1F agonists)
RN 182564-21-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-22-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-(3-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-23-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-(4-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-24-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-furanylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-25-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(tetrahydro-2-furanyl)methyl]-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-36-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-methoxy-N-methyl-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 201857-22-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1-methyl-4-piperidinyl)-N-phenyl- (CA INDEX NAME)



RN 201857-23-0 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1-methyl-4-piperidinyl)-N-(phenylmethyl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:124013 CAPLUS
DN 128:192544
OREF 128:38039a,38042a
TI Preparation of indole and carbazole derivatives as serotonin agonists
IN Johnson, Kirk W.; Phebus, Lee A.
PA Eli Lilly and Company, USA; Johnson, Kirk W.; Phebus, Lee A.
SO PCT Int. Appl., 271 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806402	A1	19980219	WO 1997-US14097	19970812
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5962473	A	19991005	US 1997-906770	19970805
	CA 2263550	A1	19980219	CA 1997-2263550	19970812
	EP 824917	A2	19980225	EP 1997-306130	19970812
	EP 824917	A3	20000830		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 9740615	A	19980306	AU 1997-40615	19970812
	AU 716904	B2	20000309		
	BR 9711147	A	19990817	BR 1997-11147	19970812
	CN 1233180	A	19991027	CN 1997-198718	19970812
	HU 9902405	A2	20000428	HU 1999-2405	19970812
	HU 9902405	A3	20021128		
	NZ 334029	A	20000728	NZ 1997-334029	19970812
	JP 2000516233	T	20001205	JP 1998-509943	19970812
	CZ 289998	B6	20020515	CZ 1999-440	19970812
	KR 2000035789	A	20000626	KR 1999-701285	19990213
	NO 9900701	A	19990416	NO 1999-701	19990215
	US 6380201	B1	20020430	US 1999-262726	19990304
PRAI	US 1996-24096P	P	19960816		
	US 1997-906770	A3	19970805		
	WO 1997-US14097	W	19970812		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 128:192544
IT 182564-21-2P 182564-22-3P 182564-23-4P
182564-24-5P 182564-25-6P 201857-22-9P
201857-23-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole and carbazole derivs. as 5-HT agonists)
RN 182564-21-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-22-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-(3-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-23-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-(4-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-24-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-furanylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-25-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(tetrahydro-2-furanyl)methyl]-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 201857-22-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1-methyl-4-piperidinyl)-N-phenyl- (CA INDEX NAME)



RN 201857-23-0 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1-methyl-4-piperidinyl)-N-(phenylmethyl)- (CA INDEX NAME)



IT 182564-36-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indole and carbazole derivs. as 5-HT agonists)
RN 182564-36-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-methoxy-N-methyl-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:55467 CAPLUS
DN 128:127937
OREF 128:25131a,25134a
TI Preparation of 3-(4-piperidinyl)indoles as 5-HT1F agonists
IN Audia, James Edmund; Dressman, Bruce Anthony; Droste, James Joseph; Fritz, James Erwin; Kaldor, Stephen Warren; Koch, Daniel James; Krushinski, Joseph Herman, Jr.; Nissen, Jeffrey Scott; Rocco, Vincent Patrick; Schaus, John Mehnert; Thompson, Dennis Charles
PA Eli Lilly and Co., USA
SO U.S., 49 pp., Cont.-in-part of U.S. Ser. No. 407,553, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5708008	A	19980113	US 1996-619783	19960320
	CA 2215322	A1	19960926	CA 1996-2215322	19960315
	WO 9629075	A1	19960926	WO 1996-US3500	19960315
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9653112	A	19961008	AU 1996-53112	19960315
	AU 702322	B2	19990218		
	CN 1184425	A	19980610	CN 1996-193881	19960315
	JP 11502816	T	19990309	JP 1996-528501	19960315
	HU 9800417	A2	19990628	HU 1998-417	19960315
	HU 9800417	A3	20010428		
	AT 198332	T	20010115	AT 1996-301845	19960319
	ES 2153078	T3	20010216	ES 1996-301845	19960319
	BR 9601061	A	19980106	BR 1996-1061	19960320
	NO 9704220	A	19971104	NO 1997-4220	19970912
	US 5962474	A	19991005	US 1997-977526	19971124
	GR 3035487	T3	20010531	GR 2001-400330	20010228
PRAI	US 1995-407553	B2	19950320		
	WO 1996-US3500	W	19960315		
	US 1996-619783	A3	19960320		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 128:127937
IT 182564-21-2P 182564-22-3P 182564-23-4P
182564-24-5P 182564-25-6P 201857-22-9P
201857-23-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-piperidinyl)indoles as 5-HT1F agonists)
RN 182564-21-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-22-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-(3-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-23-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-(4-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-24-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-furanylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-25-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(tetrahydro-2-furanyl)methyl]-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 201857-22-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1-methyl-4-piperidinyl)-N-phenyl- (CA INDEX NAME)



RN 201857-23-0 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1-methyl-4-piperidinyl)-N-(phenylmethyl)- (CA INDEX NAME)



IT 182564-36-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(4-piperidinyl)indoles as 5-HT1F agonists)
RN 182564-36-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-methoxy-N-methyl-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1996:646482 CAPLUS
DN 125:275668
OREF 125:51553a,51556a
TI Preparation of 3-(4-piperidyl)indoles and analogs as 5-HT1F agonists
IN Audia, James Edmund; Dressmann, Bruce Anthony; Droste, James Joseph; Fritz, James Erwin; Kaldor, Stephen Warren; Koch, Daniel James; Krushinski, Joseph Herman, Jr.; Thompson, Dennis Charles; Nissen, Jeffrey Scott; et al.
PA Eli Lilly and Co., USA
SO Eur. Pat. Appl., 82 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 733628	A1	19960925	EP 1996-301845	19960319
	EP 733628	B1	20001227		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2215322	A1	19960926	CA 1996-2215322	19960315
	WO 9629075	A1	19960926	WO 1996-US3500	19960315
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9653112	A	19961008	AU 1996-53112	19960315
	AU 702322	B2	19990218		
	CN 1184425	A	19980610	CN 1996-193881	19960315
	JP 11502816	T	19990309	JP 1996-528501	19960315
	HU 9800417	A2	19990628	HU 1998-417	19960315
	HU 9800417	A3	20010428		
	AT 198332	T	20010115	AT 1996-301845	19960319
	ES 2153078	T3	20010216	ES 1996-301845	19960319
	BR 9601061	A	19980106	BR 1996-1061	19960320
	NO 9704220	A	19971104	NO 1997-4220	19970912
	GR 3035487	T3	20010531	GR 2001-400330	20010228
PRAI	US 1995-407553	A	19950320		
	WO 1996-US3500	W	19960315		

OS MARPAT 125:275668
IT 182564-21-2P 182564-22-3P 182564-23-4P
182564-24-5P 182564-25-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-piperidyl)indoles and analogs as 5-HT1F agonists)
RN 182564-21-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-22-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-(3-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-23-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-(4-pyridinylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-24-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-furanylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 182564-25-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(tetrahydro-2-furanyl)methyl]-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



IT 182564-36-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(4-piperidyl)indoles and analogs as 5-HT1F agonists)
RN 182564-36-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-methoxy-N-methyl-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



OSC.G 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

L11 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1996:250648 CAPLUS
DN 124:331700
OREF 124:61201a,61204a
TI Comparison of "electric shapes" of some indole derivatives which are competitors of serotonin
AU Laszlo, Tarko
CS Inst. Chimie Organica, Academia Romana, Bucharest, Rom.
SO Revista de Chimie (Bucharest) (1996), 47(3), 238-43
CODEN: RCBUAU; ISSN: 0034-7752
PB CHIMINFORM DATA
DT Journal
LA Romanian
IT 116480-55-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(comparison of "elec. shapes" of some indole derivs. which are competitors of serotonin)
RN 116480-55-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



L11 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1994:124110 CAPLUS
DN 120:124110
OREF 120:21649a,21652a
TI Three-dimensional quantitative structure-activity relationships of 5-HT receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA methods
AU Agarwal, Atul; Pearson, Philip P.; Taylor, Ethan Will; Li, Hong B.; Dahlgren, Torsten; Herslof, Margareta; Yang, Youhua; Lambert, Georgina; Nelson, David L.; et al.
CS Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA
SO Journal of Medicinal Chemistry (1993), 36(25), 4006-14
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 120:124110
IT 116480-55-8
RL: BIOL (Biological study)
(mol. modeling, structure alignment and activity relationships as 5-HT receptor antagonist or agonist)
RN 116480-55-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



IT 152879-60-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and mol. modeling, structure alignment and activity relationships as 5-HT receptor antagonist or agonist)
RN 152879-60-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1,2,3,6-tetrahydro-1-propyl-4-pyridinyl)- (CA INDEX NAME)



OSC.G 47 THERE ARE 47 CAPLUS RECORDS THAT CITE THIS RECORD (48 CITINGS)

L11 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1992:165759 CAPLUS
DN 116:165759
OREF 116:27779a,27782a
TI The structure-activity relationship of inhibitors of serotonin uptake and receptor binding
AU Hansch, Corwin; Caldwell, Jonathan
CS Dep. Chem., Pomona Coll., Claremont, CA, 91711, USA
SO Journal of Computer-Aided Molecular Design (1991), 5(5), 441-53
CODEN: JCADEQ; ISSN: 0920-654X
DT Journal
LA English
IT 116480-55-8
RL: BIOL (Biological study)
(serotonin uptake and receptor binding inhibition by, MSBAR and QSAR study of)
RN 116480-55-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

L11 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1989:423389 CAPLUS
DN 111:23389
OREF 111:4069a,4072a
TI Preparation of 3-(4-piperidinyl)- and 3-(1,2,3,6-tetrahydro-4-pyridinyl)indoles as antimigraine agents
IN Oxford, Alexander William; Coates, Ian Harold; Butina, Darko
PA Glaxo Group Ltd., UK
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 303506	A2	19890215	EP 1988-307498	19880812
	EP 303506	A3	19900926		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ZA 8805923	A	19890726	ZA 1988-5923	19880811
	JP 01131174	A	19890524	JP 1988-201838	19880812
	US 5066660	A	19911119	US 1990-570513	19900821
PRAI	GB 1987-19167	A	19870813		
	US 1988-231260	B1	19880812		

OS MARPAT 111:23389
IT 116480-55-8P 121206-43-7P 121206-44-8P
121206-54-0P 121206-55-1P 121206-56-2P
121206-58-4P 121206-59-5P 121206-60-8P

121206-61-9P 121206-62-0P 121206-67-5P
121206-81-3P 121227-83-6P 121230-32-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antimigraine agent)

RN 116480-55-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 121206-43-7 CAPLUS
CN 1H-Indole-5-carboxamide, 1-methyl-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-, ethanedioate (1:?) (CA INDEX NAME)

CM 1

CRN 121206-42-6
CMF C16 H19 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 121206-44-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-methyl-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 121206-54-0 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-phenylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 121206-55-1 CAPLUS
CN 1H-Indole-5-carboxamide, N-(1-methylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 121206-56-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-(1-methylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 121206-55-1
CMF C18 H23 N3 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 121206-58-4 CAPLUS
CN 1H-Indole-5-carboxamide, N,N-dimethyl-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-, ethanedioate (1:?) (CA INDEX NAME)

CM 1

CRN 121206-57-3
CMF C17 H21 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 121206-59-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-(1-methylethyl)-3-(1-methyl-4-piperidinyl)-, hydrochloride (1:?) (CA INDEX NAME)





RN 121206-60-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-(1-methylethyl)-3-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)



RN 121206-61-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1-methyl-4-piperidinyl)-N-(2-phenylethyl)-,
hydrochloride (1:?) (CA INDEX NAME)





RN 121206-62-0 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 121206-67-5 CAPLUS
CN 1H-Indole-5-carboxamide, 1-methyl-3-(1-methyl-4-piperidinyl)-,
ethanedioate (1:?) (CA INDEX NAME)

CM 1

CRN 121206-66-4
CMF C16 H21 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 121206-81-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-(phenylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 121227-83-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-(phenylmethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 121230-32-8 CAPLUS
CN 1H-Indole-5-carboxamide, N,N-dimethyl-3-(1-methyl-4-piperidinyl)-, ethanedioate (1:?) (CA INDEX NAME)

CM 1

CRN 121230-31-7

CMF C17 H23 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

L11 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1988:521996 CAPLUS
DN 109:121996
OREF 109:20143a,20146a
TI Molecular determinants for recognition of RU 24696 analogs at central 5-hydroxytryptamine recognition sites: use of a bilinear function and substituent volumes to describe steric fit
AU Taylor, Ethan Will; Nikam, Sham S.; Lambert, Georgina; Martin, Arnold R.; Nelson, David L.
CS Coll. Pharm., Univ. Arizona, Tucson, AZ, 85721, USA
SO Molecular Pharmacology (1988), 34(1), 42-53
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English
IT 116480-55-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and hydroxytryptamine receptor site binding of, QSAR study of)
RN 116480-55-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (CA INDEX NAME)



OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)



Hy 14

```
ENTER (DIS), GRA, NOD, BON OR ?:end
L5   STRUCTURE CREATED

=> s l5
SAMPLE SEARCH INITIATED 12:01:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    13110 TO ITERATE

 15.3% PROCESSED     2000 ITERATIONS                              10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       255339 TO   269061
PROJECTED ANSWERS:             826 TO     1796

L6           10 SEA SSS SAM L5

=> s l5 ful
FULL SEARCH INITIATED 12:01:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   261651 TO ITERATE

100.0% PROCESSED   261651 ITERATIONS                          1475 ANSWERS
SEARCH TIME: 00.00.14

L7         1475 SEA SSS FUL L5

=> d l1
L1 HAS NO ANSWERS
L1               STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RSPEC   1 14
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

=> d his l3

     (FILE 'REGISTRY' ENTERED AT 11:56:13 ON 20 OCT 2009)
L3   1216 S L1 FUL

=> s l7 not l3
L8   265 L7 NOT L3

=> d scan

L8   265 ANSWERS   REGISTRY COPYRIGHT 2009 ACS on STN
IN   1H-Indole-7-carboxamide, 5-(3,4-difluorophenyl)-3-(1,1-dioxido-4-
     thiepanyl)-
MF   C21 H20 F2 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	187.32	390.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.10

FILE 'CAPLUS' ENTERED AT 12:02:16 ON 20 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Oct 2009 VOL 151 ISS 17
FILE LAST UPDATED: 19 Oct 2009 (20091019/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l8
L9            2 L8

=> d bib abs 1-2

L9   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2008:1180115  CAPLUS
DN   149:425786
TI   Preparation of indolecarboxamide derivatives for use as IKK2 inhibitors
IN   Boehm, Jeffrey Charles; Busch-Petersen, Jakob; Fu, Wei; Jin, Qi; Kerns,
     Jeffrey K.; Li, Huijie; Lin, Guoliang; Lin, Xichen; Neipp, Christopher E.
PA   Smithkline Beecham Corporation, USA
SO   PCT Int. Appl., 245pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2008118724        A1    20081002    WO 2008-US57583        20080320
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2007-896558P      P     20070323
OS   MARPAT 149:425786
GI
```



I



II

AB Title compds. I [R1 = YZ; R2 = bicyclo group or (un)substituted heterocycloalkyl containing S, S(O), or SO2; R3 and R4 independently = H or F; Y = bond, alkylene, alkenylene, or alkynylene; Z = (un)substituted aryl or heteroaryl; m = 0 or 1; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as IKK2 inhibitors. Thus, e.g., II was prepared by bromination of 1-(1,1-dimethylethyl) 7-Me 2,3-dihydro-1H-1,7-dicarboxylate (preparation given) followed by deprotection, oxidation, condensation with tetrahydro-4H-thiopyran-4-one, protection, oxidation, deprotection/hydrolysis, amidation with ammonia, and coupling with phenylboronic acid. Select I were evaluated in IKK2 assays and demonstrated a pIC50 of about 5.0 to about 8.5. I were disclosed as therapeutic agents for the inhibition of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and chronic obstructive pulmonary disease.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:673109 CAPLUS
DN 143:172754
TI Preparation of 7-indolecarboxamides as IKK2 kinase inhibitors for the treatment of such as inflammatory and tissue repair disorders
IN Baldwin, Ian Robert; Bamborough, Paul; Christopher, John Andrew; Kerns, Jeffrey K.; Longstaff, Timothy; Miller, David Drysdale
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005067923	A1	20050728	WO 2005-GB85	20050113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005205090	A1	20050728	AU 2005-205090	20050113
CA 2552953	A1	20050728	CA 2005-2552953	20050113

	EP 1703905	A1	20060927	EP 2005-701855	20050113
	EP 1703905	B1	20081112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
	CN 1933830	A	20070321	CN 2005-80008362	20050113
	BR 2005006802	A	20070529	BR 2005-6802	20050113
	JP 2007517848	T	20070705	JP 2006-548393	20050113
	AT 413877	T	20081115	AT 2005-701855	20050113
	ES 2317184	T3	20090416	ES 2005-701855	20050113
	ZA 2006004855	A	20071128	ZA 2006-4855	20060613
	IN 2006DN03579	A	20070831	IN 2006-DN3579	20060621
	US 20080269200	A1	20081030	US 2006-597154	20060713
	MX 2006008080	A	20060920	MX 2006-8080	20060714
	NO 2006003676	A	20061013	NO 2006-3676	20060815
	HK 1098047	A1	20090529	HK 2007-102877	20070316
PRAI	GB 2004-895	A	20040115		
	WO 2005-GB85	W	20050113		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:172754; MARPAT 143:172754

GI



AB Title compds. I [wherein R1, R2 = H, halo, alkylene, alkenylene, (hetero)aryl, etc., and salts, solvates, or physiol. functional derivs. thereof] were prepared as IKK2 kinase inhibitors. For instance, Pd-catalyzed coupling of Boc-protected bromide II (preparation given) with phenylboronic acid followed by deprotection with HCl gave 7-indolecarboxamide III. Most invented compds. were found to have activity >4.8 in the IKK2 assay, in which the degree of phosphorylation of GST-IκBα was measured as a ratio of specific 665 nm energy transfer signal to reference europium 620 nm signal. Therefore, I and their pharmaceutical compns. are useful in the treatment and prevention of disease states mediated by IKK2 mechanisms, including inflammatory and tissue repair disorders.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:1180115 CAPLUS

DN 149:425786

TI Preparation of indolecarboxamide derivatives for use as IKK2 inhibitors

IN Boehm, Jeffrey Charles; Busch-Petersen, Jakob; Fu, Wei; Jin, Qi; Kerns, Jeffrey K.; Li, Huijie; Lin, Guoliang; Lin, Xichen; Neipp, Christopher E.

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 245pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008118724	A1	20081002	WO 2008-US57583	20080320

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2007-896558P P 20070323
OS MARPAT 149:425786
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l1
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1 14
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

=> d his l3

(FILE 'REGISTRY' ENTERED AT 11:56:13 ON 20 OCT 2009)
L3 1216 S L1 FUL

=> d his l4

(FILE 'CAPLUS' ENTERED AT 11:58:51 ON 20 OCT 2009)
L4 5 S L3

```
=> d bib 1-5

L9   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2008:1180115  CAPLUS
DN   149:425786
TI   Preparation of indolecarboxamide derivatives for use as IKK2 inhibitors
IN   Boehm, Jeffrey Charles; Busch-Petersen, Jakob; Fu, Wei; Jin, Qi; Kerns,
     Jeffrey K.; Li, Huijie; Lin, Guoliang; Lin, Xichen; Neipp, Christopher E.
PA   Smithkline Beecham Corporation, USA
SO   PCT Int. Appl., 245pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2008118724        A1    20081002    WO 2008-US57583        20080320
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2007-896558P      P     20070323
OS   MARPAT 149:425786
RE.CNT  1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2005:673109  CAPLUS
DN   143:172754
TI   Preparation of 7-indolecarboxamides as IKK2 kinase inhibitors for the
     treatment of such as inflammatory and tissue repair disorders
IN   Baldwin, Ian Robert; Bamborough, Paul; Christopher, John Andrew; Kerns,
     Jeffrey K.; Longstaff, Timothy; Miller, David Drysdale
PA   Smithkline Beecham Corporation, USA
SO   PCT Int. Appl., 169 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005067923        A1    20050728    WO 2005-GB85           20050113
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
```

```
     AU 2005205090         A1    20050728    AU 2005-205090          20050113
     CA 2552953            A1    20050728    CA 2005-2552953         20050113
     EP 1703905            A1    20060927    EP 2005-701855          20050113
     EP 1703905            B1    20081112
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS
     CN 1933830            A     20070321    CN 2005-80008362        20050113
     BR 2005006802         A     20070529    BR 2005-6802            20050113
     JP 2007517848         T     20070705    JP 2006-548393          20050113
     AT 413877             T     20081115    AT 2005-701855          20050113
     ES 2317184            T3    20090416    ES 2005-701855          20050113
     ZA 2006004855         A     20071128    ZA 2006-4855            20060613
     IN 2006DN03579        A     20070831    IN 2006-DN3579          20060621
     US 20080269200        A1    20081030    US 2006-597154          20060713
     MX 2006008080         A     20060920    MX 2006-8080            20060714
     NO 200600367 6        A     20061013    NO 2006-3676            20060815
     HK 1098047            A1    20090529    HK 2007-102877          20070316
PRAI GB 2004-895           A     20040115
     WO 2005-GB85          W     20050113
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   CASREACT 143:172754; MARPAT 143:172754
OSC.G   4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT  1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d bib abs l4 1-5

L4   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2009:675762  CAPLUS
DN   151:8309
TI   Preparation of novel indolecarboxamides as IKK2 inhibitors
IN   Deng, Jianghe; Kerns, Jeffrey K.; Jin, Qi; Lin, Guoliang; Lin, Xichen;
     Lindenmuth, Michael; Neipp, Christopher; Nie, Hong; Thomas, Sonia M.;
     Widdowson, Katherine L.
PA   USA
SO   U.S. Pat. Appl. Publ., 164pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 20090143372       A1    20090604    US 2007-931189          20071031
PRAI US 2007-931189              20071031
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 151:8309
GI
```



I



II

AB The title compds. I [R1 = XYZ, tetrahydroisoquinolinyl, dihydroisoindolyl; X = (un)substituted Ph, heteroaryl, etc.; Y = a bond or alkylene; Z = NR4R5 or heterocycloalkyl; R2, R3 = H, F, Cl; R4 = H, alkyl (optionally substituted with one hydroxy or one methoxy group); R5 = H, heterocycloalkyl, alkoxy, etc.; U = a bond, alkylene or alkenylene; V = Ph, 5-6 membered heteroaryl, 5-7 membered heterocycloalkyl, etc.] which are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease), were prepared E.g., a multi-step synthesis of II, starting from indoline, was given. Selected compds. I were tested for activity against IKK2 (data given for representative compds. I). The invention is further directed to pharmaceutical compns. comprising a compound I. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound I or a pharmaceutical composition comprising a compound I.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:590757 CAPLUS
DN 147:30940
TI Preparation of indolecarboxamide derivatives as inhibitors of kinase activity
IN Kerns, Jeffrey K.; Busch-Petersen, Jakob; Li, Huijie; Boehm, Jeffrey Charles; Nie, Hong; Taggart, John J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007062318	A2	20070531	WO 2006-US61018	20061117

WO 2007062318 A3 20080117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 1948187 A2 20080730 EP 2006-846335 20061117
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
JP 2009516702 T 20090423 JP 2008-541484 20061117
US 20080269291 A1 20081030 US 2008-93750 20080515
PRAI US 2005-738393P P 20051118
WO 2006-US61018 W 20061117
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 147:30940
GI



I



II

AB The title compds. with general formula I [wherein X = O, S, S(O), S(O)2, etc,; R1 = H, (un)substituted alkyl, haloalkyl, heterocycloalkyl, etc.; R2 = (un)substituted alkyl, aryl, cycloalkyl, etc.; R3 = independently OH, oxo, alkyl, or haloalkyl; m = 1-3] or pharmaceutically acceptable salts thereof were prepared for the treatment of disorders associated with inappropriate IKK2 activities. In particular, I can be used for the treatment and prevention of inflammatory and tissue repair disorders, including rheumatoid arthritis, asthma, and COPD. For example, compound II was prepared in a multi-step synthesis. II exhibited IKK2 inhibitory activity with pIC50 value of 4.6 in IKK2 assay.
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:33976 CAPLUS
DN 146:142511

TI Preparation of novel indolecarboxamides as IKK2 inhibitors

IN Deng, Jianghe; Kerns, Jeffrey K.; Jin, Qi; Lin, Guoliang; Lin, Xichen; Lindenmuth, Michael; Neipp, Christopher E.; Nie, Hong; Thomas, Sonia M.; Widdowson, Katherine L.

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 390 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007005534	A2	20070111	WO 2006-US25402	20060628
	WO 2007005534	A3	20070426		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2006266028	A1	20070111	AU 2006-266028	20060628
	CA 2613068	A1	20070111	CA 2006-2613068	20060628
	EP 1896014	A2	20080312	EP 2006-785861	20060628
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	JP 2009500338	T	20090108	JP 2008-519569	20060628
	BR 200611674	A2	20090428	BR 2006-11674	20060628
	ZA 2007009948	A	20090429	ZA 2007-9948	20071119
	IN 2007DN09298	A	20080627	IN 2007-DN9298	20071203
	MX 2007016541	A	20080307	MX 2007-16541	20071218
	KR 2008021077	A	20080306	KR 2007-730656	20071228
	NO 2008000457	A	20080129	NO 2008-457	20080124
	CN 101247804	A	20080820	CN 2006-80030448	20080221
PRAI	US 2005-695256P	P	20050630		
	WO 2006-US25402	W	20060628		

OS MARPAT 146:142511

GI



I



II

AB The title compds. I [R1 = XYZ, tetrahydroisoquinolinyl, dihydroisoindolyl; X = (un)substituted Ph, heteroaryl, etc.; Y = a bond or alkylene; Z = NR4R5 or heteroocycloalkyl; R2, R3 = H, F, Cl; R4 = H, alkyl (optionally substituted with one hydroxy or one methoxy group); R5 = H, heterocycloalkyl, alkoxy, etc.; U = a bond, alkylene or alkenylene; V = Ph, 5-6 membered heteroaryl, 5-7 membered heterocycloalkyl, etc.] which are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease), were prepared E.g., a multi-step synthesis of II, starting from indoline, was given. Selected compds. I were tested for activity against IKK2 (data given for representative compds. I). The invention is further directed to pharmaceutical compns. comprising a compound I. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound I or a pharmaceutical composition comprising a compound I.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:298630 CAPLUS
DN 144:350542
TI Indole derivatives as IKK2 inhibitors and their preparations, pharmaceutical compositions, and use for treatment of diseases associated with inappropriate IKK2 activity such as rheumatoid arthritis, asthma and chronic obstructive pulmonary disease
IN Kerns, Jeffrey K.; Lindenmuth, Michael; Lin, Xichen; Nie, Hong; Thomas, Sonia M.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2006034317	A2	20060330	WO 2005-US33752	20050921
	WO 2006034317	A3	20070419		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2005286795	A1	20060330	AU 2005-286795	20050921
	CA 2581180	A1	20060330	CA 2005-2581180	20050921
	EP 1793826	A2	20070613	EP 2005-798511	20050921
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101060842	A	20071024	CN 2005-80039763	20050921
	JP 2008513500	T	20080501	JP 2007-532632	20050921
	BR 2005015524	A	20080729	BR 2005-15524	20050921
	ZA 2007002035	A	20081126	ZA 2007-2035	20070308
	US 20070254873	A1	20071101	US 2007-575416	20070316
	MX 2007003283	A	20070518	MX 2007-3283	20070320
	IN 2007DN02158	A	20070803	IN 2007-DN2158	20070320
	NO 2007001988	A	20070418	NO 2007-1988	20070418
	KR 2007057969	A	20070607	KR 2007-709055	20070420
PRAI	US 2004-611761P	P	20040921		
	US 2005-695454P	P	20050630		
	WO 2005-US33752	W	20050921		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 144:350542

GI



AB The invention is directed to indole carboxamide derivs. of formula I. Compds. of formula I wherein R1 is H, halo or YZ; R2 and R3 are independently H, F or Cl; Y is a bond, C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene; Z is (un)substituted (hetero)aryl; U is a bond, C1-6 alkylene or C2-6 alkenylene; V is (un)substituted Ph, (un)substituted 5-

or 6-membered heteroaryl, (un)substituted 5- to 7-membered heterocycloalkyl, (un)substituted C5-7 cycloalkyl or (un)substituted C5-7 cycloalkenyl; and their pharmaceutically acceptable salts, solvates, or polymorphs thereof are claimed in this invention. The compds. of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKss) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compns. comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Example compound II was prepared by N-Boc protection of indoline followed by acylation with Me chloroformate to give Me 1-(tert-butoxycarbonyl)indoline-7-carboxylate, which underwent bromination to give 5-bromo derivative, which was deprotected; the resulting Me 5-bromoindoline-7-carboxylate was dehydrated to give the Me 5-bromoindolecarboxylate, which upon hydrolysis gave the 5-bromo-7-indolecarboxylic acid, which underwent cross-coupling with phenylboronic acid; the resulting 5-phenylindole-7-carboxylic acid was converted to the corresponding indolecarboxamide, which underwent condensation with N-benzyl-4-piperidinone to give 3-(4-benzyl-1,2,3,6-tetrahydropyridin-4-yl)-5-phenylindole-7-carboxamide, which was subjected to hydrogenation; the resulting 3-(4-piperidinyl)-5-phenylindole-7-carboxamide was sulfonylated with 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethanesulfonyl chloride to give 3-[1-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethanesulfonyl]piperidin-4-yl]-5-methyl-1H-indole-7-carboxamide, which was reacted with to give compound II. Addnl. 315 example compds. were prepared by similar methods. All the invention compds. were evaluated for their IKK2 kinase inhibitory activity. From the IKK2 assay, it was determined that example compound II along with several other compds. have pIC50 values of 5.0 or greater. In the monocyte assay, most of the tested compound showed IC50 values or less than 10μM.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:673109 CAPLUS
DN 143:172754
TI Preparation of 7-indolecarboxamides as IKK2 kinase inhibitors for the treatment of such as inflammatory and tissue repair disorders
IN Baldwin, Ian Robert; Bamborough, Paul; Christopher, John Andrew; Kerns, Jeffrey K.; Longstaff, Timothy; Miller, David Drysdale
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005067923	A1	20050728	WO 2005-GB85	20050113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU	2005205090	A1	20050728	AU 2005-205090	20050113
CA	2552953	A1	20050728	CA 2005-2552953	20050113
EP	1703905	A1	20060927	EP 2005-701855	20050113
EP	1703905	B1	20081112		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS

CN	1933830	A	20070321	CN 2005-80008362	20050113
BR	2005006802	A	20070529	BR 2005-6802	20050113
JP	2007517848	T	20070705	JP 2006-548393	20050113
AT	413877	T	20081115	AT 2005-701855	20050113
ES	2317184	T3	20090416	ES 2005-701855	20050113
ZA	2006004855	A	20071128	ZA 2006-4855	20060613
IN	2006DN03579	A	20070831	IN 2006-DN3579	20060621
US	20080269200	A1	20081030	US 2006-597154	20060713
MX	2006008080	A	20060920	MX 2006-8080	20060714
NO	2006003676	A	20061013	NO 2006-3676	20060815
HK	1098047	A1	20090529	HK 2007-102877	20070316
PRAI GB	2004-895	A	20040115		
	WO 2005-GB85	W	20050113		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:172754; MARPAT 143:172754

GI



AB Title compds. I [wherein R1, R2 = H, halo, alkylene, alkenylene, (hetero)aryl, etc., and salts, solvates, or physiol. functional derivs. thereof] were prepared as IKK2 kinase inhibitors. For instance, Pd-catalyzed coupling of Boc-protected bromide II (preparation given) with phenylboronic acid followed by deprotection with HCl gave 7-indolecarboxamide III. Most invented compds. were found to have activity >4.8 in the IKK2 assay, in which the degree of phosphorylation of GST-IκBα was measured as a ratio of specific 665 nm energy transfer signal to reference europium 620 nm signal. Therefore, I and their pharmaceutical compns. are useful in the treatment and prevention of disease states mediated by IKK2 mechanisms, including inflammatory and tissue repair disorders.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT